Sarah Vann, APRN
Gerontology · Pleasant View, TNNPI 1609230911
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.8%), travel and lodging and education — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Abiomed at 40.4% of the total. Reporting peaked in 2022 at $1,596 and has fallen 95.7% since, to $69 in 2023.
Across 102 payments — averaging $23.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$970
- AbbVie$364
- Novo Nordisk$344
- AstraZeneca$179
- Lilly USA, LLC$159
- Sanofi-aventis U.S. LLC$89
- plus $296 from 9 others
What the payments were for
- Travel & lodging$97040%
- Food & beverage$1,38858%
- Education$422%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 2 | $970 |
| AbbVie(2 entities) | 31 | $364 |
| Novo Nordisk | 24 | $344 |
| AstraZeneca | 14 | $179 |
| Lilly USA, LLC | 10 | $159 |
| Sanofi-aventis U.S. LLC | 6 | $89 |
| Esperion Therapeutics, Inc. | 3 | $65 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $44 |
| Ironwood Pharmaceuticals, Inc | 2 | $43 |
| Novartis | 2 | $36 |
| Johnson & Johnson | 2 | $30 |
| Amgen | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| GSK | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,400 in reported general payments places this provider in the 85th percentile of 194 gerontology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 56 | $74,064 |
| OzempicSemaglutide | 49 | $60,488 |
| TrulicityDulaglutide | 28 | $41,780 |
| FarxigaDapagliflozin Propanediol | 33 | $37,295 |
| EliquisApixaban | 25 | $32,479 |
| UbrelvyUbrogepant | 12 | $19,945 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $12,087 |
| JanuviaSitagliptin Phosphate | 13 | $11,748 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $9,942 |
| MyrbetriqMirabegron | 14 | $7,702 |
| Duloxetine Hcl | 65 | $7,003 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $5,235 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $2,467 |
| Atorvastatin Calcium | 154 | $1,826 |
| Levothyroxine Sodium | 157 | $1,411 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $159 | $115,84584 claims |
| Novo NordiskOzempic | $344 | $60,48849 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $179 | $49,38146 claims |
| AbbVieUbrelvy, Synthroid | $364 | $21,31529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 194 gerontology providers in Tennessee.
Other gerontology in Pleasant View
- Jennifer MurffPleasant View$2K
- Lauren WellsPleasant View$1K
- David HughesKnoxville$476K
- Melissa RossGermantown$15K
- Erann BulmanKnoxville$13K
- Leah BalchGreeneville$9K
- Xiaoxiao ZhangNashville$8K
- Ashley WoodKnoxville$6K
- Erica LudtkeNashville$6K
- Sara ErgerCookeville$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.